Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

被引：0
|
作者：
Robert J. Fox
Rina Mehta
Timothy Pham
Julie Park
Kathleen Wilson
Machaon Bonafede
机构：
[1] Mellen Center for Multiple Sclerosis,
[2] Cleveland Clinic,undefined
[3] Bristol Myers Squibb,undefined
[4] IBM Watson Health,undefined
来源：
BMC Neurology | / 22卷
关键词：
Treatment pathway; Sankey diagram; Treatment patterns; Administrative claims database;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis
    Fox, Robert J.
    Mehta, Rina
    Pham, Timothy
    Park, Julie
    Wilson, Kathleen
    Bonafede, Machaon
    BMC NEUROLOGY, 2022, 22 (01)
  • [2] EMERGENCY ROOM UTILIZATION AMONG MULTIPLE SCLEROSIS PATIENTS TREATED WITH DISEASE-MODIFYING THERAPY IN A REAL-WORLD HYBRID CLAIMS DATABASE
    Kuranz, S.
    VALUE IN HEALTH, 2024, 27 (06) : S215 - S215
  • [3] Real-world persistence of multiple sclerosis disease-modifying therapies
    Tallantyre, Emma C.
    Dobson, Ruth
    Froud, Joseph L. J.
    St John, Frederika A.
    Anderson, Valerie M.
    Arun, Tarunya
    Buckley, Lauren
    Evangelou, Nikos
    Ford, Helen L.
    Galea, Ian
    George, Sumi
    Gray, Orla M.
    Hibbert, Aimee M.
    Hu, Mo
    Hughes, Stella E.
    Ingram, Gillian
    Kalra, Seema
    Lim, Chia-Hui E.
    Mathews, Joela T. M.
    McDonnell, Gavin V.
    Mescall, Naomi
    Norris, Sam
    Ramsay, Stephen J.
    Rice, Claire M.
    Russell, Melanie J.
    Shawe-Taylor, Marianne J.
    Williams, Thomas E.
    Harding, Katharine E.
    Robertson, Neil P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (07)
  • [4] A REAL-WORLD ASSESSMENT OF ANNUAL MULTIPLE SCLEROSIS PREVALENCE AND DISEASE-MODIFYING DRUG TREATMENT RATES USING AN ADMINISTRATIVE CLAIMS DATABASE
    Phillips, A. L.
    Munsell, M. J.
    Menzin, J.
    Dangond, F.
    Locklear, J. C.
    VALUE IN HEALTH, 2014, 17 (07) : A392 - A392
  • [5] Real-World Monitoring Costs Associated with Initiation of Disease-Modifying Therapy Among Patients with Multiple Sclerosis
    Lage, Maureen L.
    Wu, Ying
    NEUROLOGY, 2017, 88
  • [6] Real-world effectiveness of oral disease-modifying therapies for multiple sclerosis
    Thanh Phuong Pham Nguyen
    Thibault, Dylan
    Willis, Allison
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 124 - 125
  • [7] Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
    Kim, Su-Hyun
    Park, Min Su
    Kim, Woojun
    Huh, So-Young
    Shin, Hyun-June
    Hyun, Jae-Won
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2019, 15 (01): : 20 - 26
  • [8] Real-world demographics, clinical characteristics and treatment patterns in relapsing multiple sclerosis patients on disease-modifying therapy
    Ziemssen, T.
    Kurzeja, A.
    Haas, J.
    Alexander, J.
    Driessen, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 547 - 548
  • [9] Multiple sclerosis: Real-world long-term benefits of disease-modifying MS therapy
    Fyfe I.
    Nature Reviews Neurology, 2016, 12 (7) : 372 - 372
  • [10] Impact of adherence to disease-modifying drugs in multiple sclerosis: A study on Italian real-world data
    Belotti, Laura Maria Beatrice
    Di Martino, Mirko
    Zenesini, Corrado
    Vignatelli, Luca
    Baldin, Elisa
    Baccari, Flavia
    Ridley, Ben
    Nonino, Francesco
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 80
12345